Logo image of MRKR

MARKER THERAPEUTICS INC (MRKR) Stock Fundamental Analysis

NASDAQ:MRKR - Nasdaq - US57055L2060 - Common Stock - Currency: USD

1.1903  +0 (+0.03%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to MRKR. MRKR was compared to 566 industry peers in the Biotechnology industry. While MRKR seems to be doing ok healthwise, there are quite some concerns on its profitability. MRKR is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MRKR had negative earnings in the past year.
In the past year MRKR has reported a negative cash flow from operations.
MRKR had negative earnings in each of the past 5 years.
MRKR had a negative operating cash flow in each of the past 5 years.
MRKR Yearly Net Income VS EBIT VS OCF VS FCFMRKR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

MRKR has a Return On Assets (-48.73%) which is in line with its industry peers.
MRKR has a Return On Equity of -57.82%. This is in the better half of the industry: MRKR outperforms 60.60% of its industry peers.
Industry RankSector Rank
ROA -48.73%
ROE -57.82%
ROIC N/A
ROA(3y)-61.26%
ROA(5y)-61.64%
ROE(3y)-89.71%
ROE(5y)-93.87%
ROIC(3y)N/A
ROIC(5y)N/A
MRKR Yearly ROA, ROE, ROICMRKR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

MRKR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRKR Yearly Profit, Operating, Gross MarginsMRKR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, MRKR has more shares outstanding
MRKR has more shares outstanding than it did 5 years ago.
There is no outstanding debt for MRKR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MRKR Yearly Shares OutstandingMRKR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MRKR Yearly Total Debt VS Total AssetsMRKR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

MRKR has an Altman-Z score of -26.57. This is a bad value and indicates that MRKR is not financially healthy and even has some risk of bankruptcy.
MRKR has a worse Altman-Z score (-26.57) than 88.87% of its industry peers.
There is no outstanding debt for MRKR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -26.57
ROIC/WACCN/A
WACCN/A
MRKR Yearly LT Debt VS Equity VS FCFMRKR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

MRKR has a Current Ratio of 6.36. This indicates that MRKR is financially healthy and has no problem in meeting its short term obligations.
MRKR has a better Current ratio (6.36) than 65.90% of its industry peers.
MRKR has a Quick Ratio of 6.36. This indicates that MRKR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 6.36, MRKR is in the better half of the industry, outperforming 66.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.36
Quick Ratio 6.36
MRKR Yearly Current Assets VS Current LiabilitesMRKR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

MRKR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.38%.
The Revenue has grown by 99.34% in the past year. This is a very strong growth!
Measured over the past years, MRKR shows a very strong growth in Revenue. The Revenue has been growing by 99.23% on average per year.
EPS 1Y (TTM)-28.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.69%
Revenue 1Y (TTM)99.34%
Revenue growth 3Y74.52%
Revenue growth 5Y99.23%
Sales Q2Q%113.16%

3.2 Future

Based on estimates for the next years, MRKR will show a very strong growth in Earnings Per Share. The EPS will grow by 30.62% on average per year.
MRKR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 95.82% yearly.
EPS Next Y-123.21%
EPS Next 2Y-55.19%
EPS Next 3Y-3.12%
EPS Next 5Y30.62%
Revenue Next Year-61.26%
Revenue Next 2Y-51.86%
Revenue Next 3Y41.72%
Revenue Next 5Y95.82%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
MRKR Yearly Revenue VS EstimatesMRKR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
MRKR Yearly EPS VS EstimatesMRKR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150 -200 -250

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MRKR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MRKR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRKR Price Earnings VS Forward Price EarningsMRKR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRKR Per share dataMRKR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A cheap valuation may be justified as MRKR's earnings are expected to decrease with -3.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-55.19%
EPS Next 3Y-3.12%

More info and screens

0

5. Dividend

5.1 Amount

MRKR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MARKER THERAPEUTICS INC

NASDAQ:MRKR (5/1/2025, 9:18:41 PM)

1.1903

+0 (+0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-14 2025-04-14/dmh
Earnings (Next)05-13 2025-05-13
Inst Owners41.79%
Inst Owner Change0%
Ins Owners2.56%
Ins Owner Change2.93%
Market Cap12.75M
Analysts86
Price Target11.09 (831.7%)
Short Float %2.04%
Short Ratio1.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.12%
Min EPS beat(2)-10.39%
Max EPS beat(2)34.64%
EPS beat(4)2
Avg EPS beat(4)15.55%
Min EPS beat(4)-10.39%
Max EPS beat(4)43%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)20.38%
Min Revenue beat(2)-48.06%
Max Revenue beat(2)88.82%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.24%
PT rev (3m)-42.76%
EPS NQ rev (1m)-52.8%
EPS NQ rev (3m)-52.8%
EPS NY rev (1m)-49.09%
EPS NY rev (3m)-19.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-50%
Revenue NY rev (1m)61.18%
Revenue NY rev (3m)-19.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.93
P/FCF N/A
P/OCF N/A
P/B 0.69
P/tB 0.69
EV/EBITDA N/A
EPS(TTM)-1.2
EYN/A
EPS(NY)-2.68
Fwd EYN/A
FCF(TTM)-1.02
FCFYN/A
OCF(TTM)-1.02
OCFYN/A
SpS0.62
BVpS1.73
TBVpS1.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.73%
ROE -57.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.26%
ROA(5y)-61.64%
ROE(3y)-89.71%
ROE(5y)-93.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.36
Quick Ratio 6.36
Altman-Z -26.57
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.69%
EPS Next Y-123.21%
EPS Next 2Y-55.19%
EPS Next 3Y-3.12%
EPS Next 5Y30.62%
Revenue 1Y (TTM)99.34%
Revenue growth 3Y74.52%
Revenue growth 5Y99.23%
Sales Q2Q%113.16%
Revenue Next Year-61.26%
Revenue Next 2Y-51.86%
Revenue Next 3Y41.72%
Revenue Next 5Y95.82%
EBIT growth 1Y23.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3016.25%
EBIT Next 3YN/A
EBIT Next 5Y202.77%
FCF growth 1Y33.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.64%
OCF growth 3YN/A
OCF growth 5YN/A